European Medicines Agency Validates Single Tablet Regimen Filing for HIV

Article

The once-daily drug contains bictegravir and emtricitabine/tenofovir to treat adults with HIV-1.

The European Medicines Agency (EMA) fully validated a Marketing Authorization Application (MAA) for the HIV-1 combination treatment bictegravir plus emtricitabine/tenofovir alafenamide (BIC/FTC/TAF).

Data from phase 3 trials showed that BIC/FTC/TAF demonstrated high rates of virologic suppression and no treatment-emergent resistance through 48 weeks in treatment-naïve adults and virologically suppressed adults who switched regimens.

“This investigational single tablet regimen represents a potential advance in HIV treatment by combining the potency of an integrase inhibitor, bictegravir, with the demonstrated safety profile of the FTC/TAF backbone,” Norbert Bischofberger, PhD, executive vice president of Research and Development and chief scientific officer at Gilead, said in a press release. “Gilead remains at the forefront of driving innovation in HIV, without continued commitment to working to simplify and improve treatments for people living with HIV.”

The MAA contains data from 4 phase 3 clinical trials, which showed that BIC/FTC/TAF met its primary objective of non-inferiority at 48 weeks.

Three of the studies are ongoing, and investigators are examining the safety and efficacy of BIC/FTC/TAF compared with triple-therapy regimens that contain 50 mg of dolutegravir. Two of 3 studies include treatment-naïve patients and the third contains patients who are virologically suppressed.

The fourth ongoing study includes virologically suppressed patients and is designed to compare switching to BIC/FTC/TAF versus remaining on a suppressive regimen containing 2 nucleoside/nucleotide reverse transcriptase inhibitors and a boosted protease inhibitor, according to the release.

The EMA will review the BIC/FTC/TAF MMA filing under the centralized licensing procedure for all 28 member states of the European Union, plus Norway and Iceland. In the United States, a New Drug Application was submitted for BIC/FTC/TAF on June 12, 2017.

Related Videos
male pharmacist using digital tablet during inventory in pharmacy | Image Credit: sofiko14 - stock.adobe.com
Pharmacist holding medicine box in pharmacy drugstore. | Image Credit: I Viewfinder - stock.adobe.com
Pharmacy Drugstore Checkout Cashier Counter | Image Credit: Gorodenkoff - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Biosimilar pharmaceutical drug bottle on blue background. | Image Credit: Carl - stock.adobe.com
Pharmaceutical manufacture background with glass bottles with clear liquid on automatic conveyor line. | Image Credit: wacomka - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.